과제정보
This study was supported by the Basic Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (2021R1A4A5033289), and also supported by Korea Basic Science Institute (National research Facilities and Equipment Center) grant funded by the Ministry of Education (2023R1A6C101A045).
참고문헌
- Ikeda H, Lethe B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA Loss by CTL expressing an NK inhibitory receptor. Immunity 2, 199-208
- Xu Y, Zou R, Wang J, Wang ZW and Zhu X (2020) The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer. Cell Prolif 53, e12770
- Kern CH, Yang M and Liu WS (2021) The PRAME family of cancer testis antigens is essential for germline development and gametogenesis. Biol Reprod 105, 290-304
- Oberthuer A, Hero B, Spitz R, Berthold F and Fischer M (2004) The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10, 4307-4313
- Epping MT, Hart AA, Glas AM, Krijgsman O and Bernards R (2008) PRAME expression and clinical outcome of breast cancer. Br J Cancer 99, 398-403
- Cazzato G, Colagrande A, Ingravallo G et al (2022) PRAME immuno-expression in cutaneous sebaceous carcinoma: a single institutional experience. J Clin Med 11, 6936
- Cazzato G, Cascardi E, Colagrande A et al (2022) PRAME immunoexpression in 275 cutaneous melanocytic lesions: a double institutional experience. Diagnostics (Basel) 12, 2197
- Cascardi E, Cazzato G, Ingravallo G et al (2023) PReferentially Expressed Antigen in MElanoma (PRAME): preliminary communication on a translational tool able to early detect oral malignant melanoma (OMM). J Cancer 14, 628-633
- Yan H, Zhao RM, Wang ZJ, Zhao FR and Wang SL (2015) Knockdown of PRAME enhances adriamycin-induced apoptosis in chronic myeloid leukemia cells. Eur Rev Med Pharmacol Sci 19, 4827-4834
- Zhu H, Wang J, Yin J et al (2018) Downregulation of PRAME suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of p53 mediated pathway. Cell Physiol Biochem 45, 1121-1135
- Chen X, Jiang M, Zhou S et al (2023) PRAME promotes cervical cancer proliferation and migration via Wnt/β-catenin pathway regulation. Cancers (Basel) 15, 1801
- Bose M (2023) Preferentially expressed antigen in melanoma is a multifaceted cancer testis antigen with diverse roles as a biomarker and therapeutic target. Int J Transl Med 3, 334-359
- Cassalia F, Danese A, Tudurachi I et al (2024) PRAME updated: diagnostic, prognostic, and therapeutic role in skin cancer. Int J Mol Sci 25, 1582
- Qian J, Zhu ZH, Lin J et al (2011) Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome. Br J Haematol 154, 153-155
- Zhang W, Barger CJ, Eng KH et al (2016) PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget 7, 45352-45369
- Lee YK, Park UH, Kim EJ, Hwang JT, Jeong JC and Um SJ (2017) Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. Cancer Lett 403, 144-151
- Dai C and Gu W (2010) p53 post-translational modification: deregulated in tumorigenesis. Mol Med 16, 528-536
- Lee JY and Gu W (2013) SIRT1: regulator of p53 deacetylation. Genes Cancer 4, 112-117
- Riley T, Sontag E, Chen P and Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9, 402-412
- Ceribelli M, Alcalay M, Vigano MA and Mantovani R (2006) Repression of new p53 targets revealed by ChIP on chip experiments. Cell Cycle 5, 1102-1110
- Rinn JL and Huarte M (2011) To repress or not to repress: this is the guardian's question. Trends Cell Biol 21, 344-353
- Luca M, Lenzi R, Leejackson D, Gutman M, Fidler I and Bareli M (1993) p53 mutations are infrequent and do not correlate with the metastatic potential of human-melanoma cells. Int J Oncol 3, 19-22
- Weiss J, Heine M, Arden KC et al (1995) Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res 139, 137-154
- Houben R, Hesbacher S, Schmid CP et al (2011) High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One 6, e22096
- Avery-Kiejda KA, Bowden NA, Croft AJ et al (2011) p53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer 11, 203
- Pfister NT and Prives C (2017) Transcriptional regulation by wild-type and cancer-related mutant forms of p53. Cold Spring Harb Perspect Med 7, a026054
- Yeudall WA, Vaughan CA, Miyazaki H et al (2012) Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis. 33, 442-451
- Yan W, Liu G, Scoumanne A and Chen X (2008) Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res 68, 6789-6796
- Zalcenstein A, Stambolsky P, Weisz L et al (2003) Mutant p53 gain of function: repression of CD95 (Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22, 5667-5676